Table 4.
Telephone follow-up.
| Total | Confirmed COVID-19 | Unconfirmed COVID-19 | P | |
|---|---|---|---|---|
| Duration fever/low-grade fever (days), median (IQR) | 6 (2−13.8) | 4 (1.3−11.5) | 8.5 (2.3−28) | .128 |
| Duration symptoms (days), median (IQR) | 25.5 (13.8−37) | 17 (10−32) | 30 (20−48) | .005 |
| Duration follow-up (days), median (IQR) | 28 (21−39) | 29 (21−39) | 25 (20.3−37.3) | .764 |
| Number of phone calls; median (IQR) | 6 (4−8) | 6 (4−8) | 6 (4.3−8.8) | .533 |
| New symptoms during follow-up, n (%) | 30 (41.6%) | 16 (40%) | 14 (43.8%) | .812 |
| Adverse drug reactions, n (%) | 12 (16.7%) | 7 (18%) | 5 (15.6%) | 1.000 |
| Worsening during follow-up, n (%) | 19 (26.4%) | 9 (22.5%) | 10 (31.3%) | .432 |
| Additional emergency visits, n (%) | 14 (19.4%) | 6 (15%) | 8 (25%) | .373 |
| Readmission, n (%) | 1 (1.4%) | 0 | 1 (3.1%) | .444 |